Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TYMP | P19971 | 3/20 | 0.33 |
| ▸ | DPYD | Q12882 | 1/20 | 0.33 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13273574 | 0.82 | TYMP (0.43) | KMT2ATYMPDPYDUPP1LMNA | |
| SCHEMBL4094691 | 0.80 | TYMP (0.49) | TYMP | |
| SCHEMBL3412829 | 0.80 | KMT2A (0.48) | KMT2ATYMPUPP1HTTLMNA | |
| SCHEMBL10048498 | 0.80 | TYMP (0.37) | KMT2ATYMPDPYDUPP1HTT | |
| SCHEMBL3415213 | 0.77 | DPYD (0.34) | KMT2ATYMPDPYDUPP1HTT | |
| SCHEMBL10437103 | 0.73 | UPP1 (0.67) | UPP1 | |
| SCHEMBL13968219 | 0.69 | KMT2A (0.34) | KMT2ATYMP | |
| SCHEMBL9085796 | 0.66 | KMT2A (0.33) | KMT2ADPYDLMNA | |
| SCHEMBL9086161 | 0.66 | KMT2A (0.33) | KMT2ADPYDLMNA | |
| SCHEMBL1557215 | 0.65 | HPGD (0.61) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382286-B2 | Treatment of EBV and KHSV infection and associated abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20140336143-A1 | TREATMENT OF EBV AND KHSV INFECTION AND ASSOCIATED ABNORMAL CELLULAR PROLIFERATION | GILEAD PHARMASSET LLC (US) | 2014-11-13 | — | — | US | disclosed |
| US-20100168052-A1 | Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation | PHARMASSET, INC. (US) | 2010-07-01 | — | — | US | disclosed |
| US-7638502-B2 | Treatment of EBV and KHSV infection and associated abnormal cellular proliferation | PHARMASSET, INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-20070197462-A1 | Treatment of EBV and KHSV infection and associated abnormal cellular proliferation | PHARMASSET, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-7211570-B2 | Administering 5-substituted uracil-nucleosides or its pharmaceutically acceptable salt or prodrug for therapy of infected with Epstein-Barr virus or Kaposi's sarcoma-associated herpes (\"KHSV\") | PHARMASSET, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-20030176392-A1 | Administering 5-substituted uracil-nucleosides or its pharmaceutically acceptable salt or prodrug for therapy of infected with Epstein-Barr virus or Kaposi's sarcoma-associated herpes (\"KHSV\") | EMORY UNIVERSITY | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176392-A1 | Administering 5-substituted uracil-nucleosides or its pharmaceutically acceptable salt or prodrug for therapy of infected with Epstein-Barr virus or Kaposi's sarcoma-associated herpes (\"KHSV\") | UMPS, UNG, TYMP | KMT2A 687/4885TYMP 3/4885DPYD 14/4885 |
| US-20070197462-A1 | Treatment of EBV and KHSV infection and associated abnormal cellular proliferation | UMPS, ENTPD5, TK1 | KMT2A 313/4885TYMP 4/4885DPYD 76/4885 |
| US-20140336143-A1 | TREATMENT OF EBV AND KHSV INFECTION AND ASSOCIATED ABNORMAL CELLULAR PROLIFERATION | UMPS, ENTPD5, TK1 | KMT2A 313/4885TYMP 4/4885DPYD 76/4885 |
| US-20100168052-A1 | Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation | UMPS, ENTPD5, TK1 | KMT2A 313/4885TYMP 4/4885DPYD 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.